Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less
- 23 July 2003
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 57 (1) , 8-13
- https://doi.org/10.1002/pros.10268
Abstract
BACKGROUND The optimal re-screening interval is one of the most important issues to evaluate the effectiveness of screening for prostate cancer. METHODS Between 1992 and 2000, 7,026 men aged 50–78 with baseline PSA levels of 4.0 ng/ml or lower underwent screening for prostate cancer twice or more. The risk of developing prostate cancer relative to elapsed years and baseline PSA levels were investigated. RESULTS Prostate cancer was detected in a total of 127 cases (1.8%). The detection rate of prostate cancer was high between 1.6% and 5.5% at 1 year after baseline PSA measurements in men with baseline PSA levels of 2.1–4.0 ng/ml. In men with baseline PSA levels of 1.1– 2.0 ng/ml, the detection rate increased from 0.06% to 1.02% with passed years. The proportion of stage ≥T3 was high at 63% in prostate cancer cases detected between 3 and 4 years after baseline PSA levels being 1.1–2.0 ng/ml. In men with baseline PSA levels of 1.0 or lower, the cumulative detection rate of prostate cancer was low at 0.01% within 3 years, however, the detection rate increased to 0.34% after 5 or more years from baseline PSA measurements. CONCLUSIONS The re-screening interval was recommended to be 1, 1–2, and 3–5 years for men with baseline PSA levels of 2.1–4.0 ng/ml, 1.1–2.0 ng/ml, and 1.0 ng/ml or lower, respectively. Prostate 57: 8–13, 2003.Keywords
This publication has 12 references indexed in Scilit:
- Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 ng/mL or lessUrology, 2001
- Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trialPublished by Elsevier ,2001
- THE INCIDENCE OF PROSTATE CANCER IN A SCREENING POPULATION WITH A SERUM PROSTATE SPECIFIC ANTIGEN BETWEEN 2.5 AND 4.0 NG./ML.: RELATION TO BIOPSY STRATEGYJournal of Urology, 2001
- PROSTATE CANCER DETECTION IN BLACK AND WHITE MEN WITH ABNORMAL DIGITAL RECTAL EXAMINATION AND PROSTATE SPECIFIC ANTIGEN LESS THAN 4 NG./ML.Journal of Urology, 2000
- Usefulness of age-specific reference range of prostate-specific antigen for japanese men older than 60 years in mass screening for prostate cancerUrology, 2000
- PROSTATE CANCER DETECTION AT LOW PROSTATE SPECIFIC ANTIGENJournal of Urology, 2000
- DIGITAL RECTAL EXAMINATION FOR DETECTING PROSTATE CANCER AT PROSTATE SPECIFIC ANTIGEN LEVELS OF 4 NG./ML. OR LESSJournal of Urology, 1999
- The European Randomized Study of Screening for Prostate Cancer (ERSPC): An UpdateEuropean Urology, 1999
- The European randomized study of screening for prostate cancerCancer, 1997